## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.0% below STRENGTH zone (4.0-10.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Thrivent Financial for Lutherans Grows Stock Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251216T135313 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in STERIS plc (NYSE:STE) by 49.2% during the second quarter, bringing its total holdings to 159,864 shares valued at $38.4 million. This move comes as institutional ownership in STERIS nears 94.7% and the company exceeded Q2 expectations with EPS of $2.47 and revenue of $1.46 billion. Despite some insider selling, analysts maintain a "Moderate Buy" rating for STERIS with a consensus target price of $273.50, and the company has provided strong FY2026 EPS guidance.

**2. Neuberger Berman Group LLC Has $4.66 Million Stock Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251215T115851 | Somewhat-Bullish | Relevance: 100%
- Neuberger Berman Group LLC significantly increased its stake in STERIS plc (NYSE:STE) by 64.7% in Q2, bringing its total holdings to $4.66 million. Other institutional investors also adjusted their positions, and 94.69% of STERIS stock is now institutionally owned. The company recently reported strong earnings, issued a dividend, and saw insider selling activity, while analysts maintain a "Moderate Buy" rating with a consensus price target of $273.50.

**3. UV Infection Control Devices Market to Grow at 6.5% CAGR During 2024-2031; North America Leads with 39% Share - Key Players: STERIS, Getinge, Xenex**
- Source: openPR.com | 20251216T090826 | Bullish | Relevance: 90%
- The global UV Infection Control Devices Market is projected to grow at a CAGR of 6.5% from 2024 to 2031, driven by increasing awareness of hospital-acquired infections, a focus on hygiene, and the adoption of non-chemical disinfection technologies. North America, particularly the U.S. and Canada, is expected to hold the largest market share due to advanced healthcare infrastructure and strict regulations. Key market players include STERIS plc., Getinge Group, and Xenex, who lead in providing various UV-C disinfection solutions for healthcare and public settings.

**4. Royal Philips (NYSE: PHG) to acquire SpectraWAVE, adding AI coronary imaging tools**
- Source: Stock Titan | 20251215T070916 | Neutral | Relevance: 61%
- Royal Philips announced its agreement to acquire SpectraWAVE, aiming to enhance its coronary intravascular imaging and physiology portfolio with AI-powered tools like the HyperVue Imaging System and X1-FFR. This acquisition will integrate SpectraWAVE's technologies into Philips' Azurion platform, expanding treatment options for coronary artery disease. Although financial terms were not disclosed, SpectraWAVE's products hold US FDA Class 2 clearances and the deal reinforces Philips' focus on minimally invasive cardiac care and AI-driven image-guided therapy.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Forward P/E 22.6x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.8B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 22.6 |
| Current P/E | 24.7 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.1% to -1.0% (+4.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.05x) but short-term weakness (below SMA20). MACD histogram bearish (-1.71), momentum weakening. RSI neutral at 43. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.96% (CS: 23) | Neutral |
| RSI_14 | 42.7 | Neutral |
| MACD Histogram | -1.71 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 1.001x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $251.79
- **Stop Loss:** $241.77 (4.0% risk)
- **Target:** $261.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 107
- **Position Value:** $26,941.53
- **Portfolio %:** 26.94%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*